Entera Bio Ltd. (NASDAQ:ENTX) Sees Large Growth in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 104,500 shares, a growth of 59.5% from the January 31st total of 65,500 shares. Based on an average trading volume of 114,000 shares, the short-interest ratio is presently 0.9 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Entera Bio in a research report on Monday, November 11th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ENTX. Knoll Capital Management LLC raised its holdings in shares of Entera Bio by 51.5% in the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock valued at $12,470,000 after purchasing an additional 2,000,000 shares in the last quarter. Parkman Healthcare Partners LLC increased its holdings in Entera Bio by 2.4% in the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after buying an additional 9,558 shares during the last quarter. Northern Trust Corp acquired a new stake in Entera Bio in the fourth quarter valued at $450,000. Perigon Wealth Management LLC purchased a new stake in Entera Bio during the 4th quarter worth about $325,000. Finally, Signature Estate & Investment Advisors LLC acquired a new position in shares of Entera Bio during the 3rd quarter worth about $90,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Stock Up 2.6 %

NASDAQ ENTX traded up $0.05 during trading hours on Tuesday, hitting $1.98. 50,246 shares of the company were exchanged, compared to its average volume of 151,718. The firm has a market cap of $70.85 million, a price-to-earnings ratio of -7.62 and a beta of 1.62. The company has a 50 day moving average of $2.30 and a two-hundred day moving average of $2.00. Entera Bio has a 52-week low of $1.30 and a 52-week high of $3.35.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.